Abstract
The role of nuclear medicine in the management of oncological patients has expanded during last two decades. The number of radiopharmaceuticals contributing to the realization of theranostics/radiotheranostics in the context of personalized medicine is increasing. This review is focused on the examples of targeted (radio)pharmaceuticals for the imaging and therapy of neuroendocrine neoplasms (NENs), prostate cancer, and breast cancer. These examples strongly demonstrate the tendency of nuclear medicine development towards personalized medicine.
Subject
Drug Discovery,Pharmaceutical Science,Molecular Medicine
Reference188 articles.
1. Radionuclides for imaging and therapy in oncology;Velikyan,2014
2. In vivo binding of [68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours — impact of peptide mass
3. Measuring her2-Expression in metastatic breast cancer using 68ga-aby025 pet/ct;Sorensen;Eur. J. Nucl. Med. Mol. Imaging,2014
4. Gmp compliant preparation of a 68gallium-Labeled affibody analogue for breast cancer patient examination: First-In-Man;Velikyan;Eur. J. Nucl. Med. Mol. Imaging,2014
5. Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [68Ga]ABY-025 Affibody PET/CT
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献